[go: up one dir, main page]

GB0610868D0 - Treatment of pain - Google Patents

Treatment of pain

Info

Publication number
GB0610868D0
GB0610868D0 GBGB0610868.2A GB0610868A GB0610868D0 GB 0610868 D0 GB0610868 D0 GB 0610868D0 GB 0610868 A GB0610868 A GB 0610868A GB 0610868 D0 GB0610868 D0 GB 0610868D0
Authority
GB
United Kingdom
Prior art keywords
pain
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0610868.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntaxin Ltd
Allergan Inc
Original Assignee
Syntaxin Ltd
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntaxin Ltd, Allergan Inc filed Critical Syntaxin Ltd
Priority to GBGB0610868.2A priority Critical patent/GB0610868D0/en
Publication of GB0610868D0 publication Critical patent/GB0610868D0/en
Priority to PCT/GB2007/002042 priority patent/WO2007138336A2/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
GBGB0610868.2A 2006-06-01 2006-06-01 Treatment of pain Ceased GB0610868D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0610868.2A GB0610868D0 (en) 2006-06-01 2006-06-01 Treatment of pain
PCT/GB2007/002042 WO2007138336A2 (en) 2006-06-01 2007-06-01 Treatment of pain by single chain, polypeptide fusion protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0610868.2A GB0610868D0 (en) 2006-06-01 2006-06-01 Treatment of pain

Publications (1)

Publication Number Publication Date
GB0610868D0 true GB0610868D0 (en) 2006-07-12

Family

ID=36694796

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0610868.2A Ceased GB0610868D0 (en) 2006-06-01 2006-06-01 Treatment of pain

Country Status (2)

Country Link
GB (1) GB0610868D0 (en)
WO (1) WO2007138336A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
NZ585108A (en) 2007-10-23 2012-09-28 Allergan Inc Methods of treating urogenital-neurological disorders using modified clostridial toxins
AU2009288088B2 (en) 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
CA2588292C (en) * 2004-12-01 2019-01-15 Health Protection Agency Non-cytotoxic protein conjugates

Also Published As

Publication number Publication date
WO2007138336A3 (en) 2008-12-11
WO2007138336A2 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
GB0610867D0 (en) Treatment of pain
IL193748A0 (en) Treatment of pain
IL248204A0 (en) Combination treatment of cd38-expressing tumors
GB0602178D0 (en) Therapeutic treatment
HK1207578A1 (en) Treatment of synucleinopathies
IL198663A0 (en) Tissue treatment methods
IL197315A0 (en) Treatment of cancer
EP2049139A4 (en) Treatment of ras-expressing tumors
GB0608655D0 (en) Therapeutic Treatment
HK1255227A1 (en) Pain treatment
ZA200806808B (en) Treatment of stressed patients
EP1968591A4 (en) Treatment of synucleinopathies
IL213703A (en) Compounds for the treatment of pain and other diseases
GB0610909D0 (en) Therapeutic treatment
ZA201000225B (en) Treatment of depression
GB0610868D0 (en) Treatment of pain
IL202639A0 (en) Treatment of neuropathic pain
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0723100D0 (en) Treatment of HFnEF
EP2124950A4 (en) Treatment of pain with naloxone
EP2164494A4 (en) Methods of treatment
GB0618060D0 (en) Treatment of polyamides
GB0616450D0 (en) Treatment of pain
GB0623740D0 (en) Treatment of disease
GB0611417D0 (en) Treatment of cndaria intoxication

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)